Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of SHR-3167 versus insulin glargine in adults with inadequately controlled type 2 diabetes on metformin with or without an SGLT2 inhibitor
CTR20244274Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-3167 in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Jan 2025; status: completed.
02
Drugs
SHR-3167
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20244274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244274.